Transcription-based drug repurposing for COVID-19

We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Killick, Richard, Ballard, Clive, Doherty, Patrick, Williams, Gareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518800/
https://www.ncbi.nlm.nih.gov/pubmed/32987033
http://dx.doi.org/10.1016/j.virusres.2020.198176
Descripción
Sumario:We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activity. Nine of these have been tested against SARS-2 and found to potently antagonise SARS-2 infection/replication, with a number now being considered for clinical trials. It is hoped that this approach may serve to broaden the spectrum of approved drugs that should be further assessed as potential anti−COVID-19 agents and may help elucidate how this seemingly disparate collection of drugs are able to inhibit SARS-2 infection/replication.

Ejemplares similares